Navigation Links
EUCODIS Bioscience Appoints Thomas Fischer as Chief Financial Officer
Date:1/30/2009

VIENNA, Austria, January 30 /PRNewswire/ -- EUCODIS Bioscience, a company developing enzymes for the chemical industry, announced today that Thomas Fischer has joined the company as Chief Financial Officer.

"We are excited about the wealth of experience that Thomas brings to EUCODIS Bioscience," said Rudy Pandjaitan, Ph.D., CEO of EUCODIS Bioscience. "His strong background in the life science industry and his close relations with the investment community will be a tremendous asset and help drive the future financial growth of the Company. Thomas joins EUCODIS Bioscience as the Company is launching its first commercial enzyme and is expanding the scope of its industrial collaborations from its current European focus into the US and Asian markets."

Most recently Mr. Fischer served as Chief Financial Officer of Austrianova, a clinical stage biopharmaceutical company that he co-founded in 2001. In this responsibility he successfully raised more than 30 million Euros in two private financing rounds. Prior to that he held senior positions at Aventis CropScience, Germany, and at Nycomed Pharma East Europe/CIS. Before joining the life science industry, Mr. Fischer spent several years in the European consumer goods and construction industries.

Mr. Fischer holds an M.B.A. from Vienna University of Economics and Business Administration, Austria, where he also received his M.Sc.

About EUCODIS Bioscience

EUCODIS Bioscience GmbH develops enzymes and biocatalytic processes that enable the chemical, pharmaceutical and other industries to establish critical manufacturing processes and to generate superior products.

Based on its proven proprietary technology and led by an experienced management team, EUCODIS Bioscience provides products and services that help its customers to improve efficiencies and to meet growing environmental requirements.

The Company commercializes its enzyme expertise and its versatile and powerful technology in development projects with industrial partners. Current partners include industry leaders such as GlaxoSmithKline, Henkel, and Lohmann Animal Health.

The Company was founded in 2007, as a demerger of the "white biotech" business unit of Eucodis GmbH, a company founded in 2004. The Company is headquartered in Austria, Europe, with subsidiaries in France and Germany.

    For more information, please visithttp://www.eucodisbioscience.com

    Company contact:

    Rudy Pandjaitan, PhD
    CEO EUCODIS Bioscience
    Brunner Strasse 59
    A-1230 Vienna
    AUSTRIA
    +43-1-86634-9241
    office@eucodisbioscience.com

    Media Contact:
    Frank Butschbacher
    Investor Relations & Communications
    +43-650-7844940
    office@butschbacher.net
   http://www.butschbacher.net


'/>"/>
SOURCE EUCODIS Bioscience
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Sangamo BioSciences Announces Fourth Quarter and Year-End 2008 Conference Call and Webcast
2. Neurocrine Biosciences Announces Conference Call and Webcast to Present Fourth Quarter and Year End 2008 Financial Results
3. BD Biosciences to Distribute FCS Express
4. MichBio Will Publish 2009 Michigan Biosciences Directory and Resource Guide
5. Cell Biosciences Introduces Kits for Oncoprotein Analysis
6. Dr. Steven L. Zelenkofske Joins Regado Biosciences as Senior Vice President, Clinical and Medical Affairs and Chief Medical Officer
7. Cyntellect Appoints Former Millipore and BD Biosciences Executives to Head Up its Product Marketing Efforts
8. Sigma-Aldrich and Sangamo BioSciences Announce the Achievement of Key Throughput Milestone in Research Reagents Agreement
9. Alliance Biosciences Announces Trade Mission to Singapore with Speaker Presentation at International Lab Design Seminar
10. Cell Biosciences Delivers Next Generation System to Stanford University
11. Regado Biosciences To Present at the 27th Annual J.P. Morgan Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... -- Houston Methodist Willowbrook Hospital has signed a ... serve as their official health care provider. As ... provide sponsorship support, athletic training services, and most ... athletes and families. "We are excited ... to bring Houston Methodist quality services and programs ...
(Date:6/23/2016)... FRANCISCO , June 23, 2016   EpiBiome ... has secured $1 million in debt financing from Silicon ... ramp up automation and to advance its drug development ... its new facility. "SVB has been an ... beyond the services a traditional bank would provide," said ...
(Date:6/23/2016)... 2016 Apellis Pharmaceuticals, Inc. today announced ... of its complement C3 inhibitor, APL-2. The trials ... dose studies designed to assess the safety, tolerability, ... in healthy adult volunteers. Forty subjects ... single dose (ranging from 45 to 1,440mg) or ...
(Date:6/23/2016)... ... 23, 2016 , ... ClinCapture, the only free validated electronic ... showcase its product’s latest features from June 26 to June 30, 2016 for ... Disrupting Clinical Trials in The Cloud during the conference. DIA (Drug Information ...
Breaking Biology Technology:
(Date:6/7/2016)... , June 7, 2016  Syngrafii Inc. and ... business relationship that includes integrating Syngrafii,s patented LongPen™ ... project. This collaboration will result in greater convenience ... credit union, while maintaining existing document workflow and ... ...
(Date:6/2/2016)... The Department of Transport Management (DOTM) ... million US Dollar project, for the , Supply ... Enrolment, and IT Infrastructure , to ... implementation of Identity Management Solutions. Numerous renowned international vendors participated ... was selected for the most compliant and innovative ...
(Date:6/2/2016)... 2016 Perimeter Surveillance & Detection ... Physical Infrastructure, Support & Other Service  The ... offers comprehensive analysis of the global Border Security ... revenues of $17.98 billion in 2016. Now: ... leader in software and hardware technologies for advanced video ...
Breaking Biology News(10 mins):